[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oesophagogastric-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oesophagogastric-cancer":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100565999","evaluation-in-humans-of-the-correlation-between-hepatotoxicity-neurotoxicity-induced-by-oxaliplatin-and-blood-levels-of-hmgb1-100565999",false,"NCT06649474","Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1","HEPATOXALI","Inclusion Criteria:\n\n* ECOG WHO Performance status = 0 or 1\n* Signed and dated informed consent\n* Patients with histological diagnosis of oesogastric or pancreatic adenocarcinoma\n* Resectable tumors\n* Patients able to have a laparoscopy\n* In case of absence of peritoneal invasion on the laparoscopy, patient candidate to a chemotherapy schedule by FLOT or FOLFOX in perioperative setting for oesogastric adenocarcinoma, or FOLFIRINOX in perioperative setting for pancreatic adenocarcinoma\n* Registration in a national health care system (CMU included)\n* Patient speak and understand the french\n\nExclusion Criteria:\n\n* Histology other than adenocarcinoma\n* Metastatic disease\n* History of previous treatment with oxaliplatine\n* History of systemic chemotherapy administration within 5 years prior to inclusion,\n* Patient with an non balanced progressive condition\u002Fdisease (liver failure, renal failure (creatinine clearance \\<30mL\u002Fmin), respiratory failure, congestive heart failure, myocardial infarction in the last 6 months, etc.),\n* Patient on curative dose anticoagulant,\n* Patient with complete dihydropyrimidine dehydrogenase deficiency (Uracilemia ≥ 150 ng\u002Fml),\n* Patient not operable for the pathology concerned,\n* Pregnant or breastfeeding woman, woman of childbearing age who has not performed a pregnancy test before the procedure,\n* Patient with legal incapacity (person deprived of liberty or under curatorship, stutorship, safeguard of justice),\n* Patient who, for psychiatric, social, family or geographical reasons, cannot be followed and\u002For comply with the requirements of the study,,\n* Discovery of peritoneal invasion during the peritoneal exploratory of the laparoscopy","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","Oesogastric and pancreatic adenocarcinomas are poor-prognosis cancers. Incidence of pancreatic cancer drastically increases to such an extent that it will become the second cause of cancer's mortality by 2030. A major challenge is to optimize the therapies for localized setting, when oxaliplatin-based chemotherapy is the standard, before and after surgical excision. Because in 50% of cases oxaliplatin triggers a grade 2-3 sinusoidal obstruction syndrome (SOS) which increases post-operative morbidity, decreases histological response to chemotherapy, increases tumor recurrence, and aggravates the risk of chemotherapy-induced peripheral neuropathy (CIPN).\n\nThere is an urgent need to better understand the biological processes involved in SOS, in order to prevent and treat it without stopping or reducing oxaliplatin administration.\n\nThe biological link between oxaliplatin and SOS has not been described, but recent murine experiments argue for HMGB1 to be the mediator released after exposure to oxaliplatin and inducing SOS, and thereafter CIPN. To date, no biomarker is established between murine and patient analyses, and the release of HMGB1 after oxaliplatin treatment and its effect on hepatic parenchyma is not described in patients. Investigators hypothesized is that HMGB1 would also been increased in patients after oxaliplatin treatment, and correlated to the development of SOS and CIPN. If confirmed, personalized treatment will be possible to target this pathway.\n\nTherefore, investigators propose to dynamically explore this hypothesis in localized oesogastric and pancreatic cancer patients who will be routinely managed by an initial laparoscopy and post-oxaliplatin surgical excision.",[26,27,28,29,30,31],"Pancreatic Cancer","Resectable Pancreatic Adenocarcinoma","Adenocarcinoma","Resectable Esophageal Cancer","Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","Oesophagogastric Cancer",[33,34,35],"resecable pancreatic, oesophageal, gastric or gastroesophageal junction adenocarcinoma.","Patients able to have a laparoscopy","chemotherapy before surgery","RECRUITING","2024-10-17",{"date":39,"type":40},"2024-10-18","ACTUAL",{"date":42,"type":40},"2024-09-06",{"date":44,"type":20},"2028-06-30",{"name":46,"class":47},"University Hospital, Clermont-Ferrand","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100520488","imac---immune-pathways-in-oesophagogastric-cancer-100520488","NCT06057220","IMaC - Immune Pathways in Oesophagogastric Cancer","Investigation of Immune Pathways and Microbiome Disruption as Drivers of Mutagenesis in Oesophagogastric Cancer","IMaC","Inclusion Criteria:\n\n1. Adult patients \\>16 years old\n2. Referred for oesophago-gastro-duodenoscopy (OGD) to investigate any of the following;\n\n   1. Symptoms including difficulty swallowing, vomiting, reflux symptoms including heartburn, anaemia, GI bleeding, upper abdominal pain and weight loss.\n   2. Oesophagitis, gastritis or GORD.\n   3. Barrett's oesophagus (BO) requiring surveillance or endoscopic therapy.\n3. Histologically confirmed OGc undergoing further investigation as part of staging such as laparoscopy and OGD or undergoing surgical resection (oesophagectomy\u002Fgastrectomy) as part of their treatment.\n\nExclusion Criteria:\n\n1. Cancers other than adenocarcinoma or squamous cell carcinoma, including but not limited to gastro-intestinal stromal tumours (GIST), mucosa associated lymphoid tissue lymphoma (MALT lymphoma) and carcinoid tumours.\n2. Patients with recurrent OGc.","17 Years",{"count":59,"type":20},310,"OBSERVATIONAL","The number of cases of oesophagogastric cancer is increasing every year. Currently, only 39% of patients with oesophageal cancer can have potentially curative treatment by the time they are diagnosed. This is because it typically presents late, and it is only when patients start to develop symptoms of advanced disease such as difficulty swallowing and weight loss, that they seek medical attention.\n\nThere are approximately 9300 new cases of oesophageal cancer in the UK each year and at 17%, it has the 5th poorest 5-year survival of all cancers in the UK.\n\nIt is diagnosed by carrying out a camera test called a gastroscopy which allows a biopsy of the cancer to be taken. This is an invasive procedure, and unlike for other types of cancer, such as bowel cancer, there is no test to risk-stratify patients at an earlier stage. Risk-stratification enables patients more likely to develop oesophagogastric cancer to be identified, which allows them to have more focused follow-up. This can potentially enable cancer to be diagnosed earlier, before the disease becomes more advanced, allowing patients to have potentially curative treatment.\n\nScientific research has identified that the healthy bacteria in the oesophagus and stomach changes as oesophagogastric cancer develops. The investigators want to see if similar changes can be identified in the healthy bacteria in the mouth which could be indicative of cancer developing in the oesophagus or stomach. The investigators then hope to use this information to develop a non-invasive risk-stratification tool that can be used to diagnose oesophagogastric cancer earlier and thereby enable more patients to be cured.",[31],"NOT_YET_RECRUITING","2023-10-04",{"date":66,"type":40},"2023-10-05",{"date":68,"type":20},"2023-10",{"date":70,"type":20},"2026-09",{"name":72,"class":47},"Royal Marsden NHS Foundation Trust",3]